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Johannes Lugauer, Claudia G6bel, Doris Haack, Georg Beck, 
Otto-Albrecht Miiller, Peter Riederer, and Helmut Beckmann 
We studied glucocorticoid receptor autoregulation and corticotropin response to dexa- 
methasone in depressed patients and controls, attempting tocontrol for the confounding 
effect of endogenous glucocorticoids. After depletion of endogenous cortisol, depressed 
patients howed an attenuated suppressibility of corticotropin by dexamethasone i  the 
face of unchanged examethasone plasma levels. [3-endorphin levels were strongly cor- 
related with adrenocorticotropic hormone (ACTH) concentrations. Although metyrapone 
administration resulted in a marked rise of glucocorticoid receptor sites per cell in 
controls, this effect was not present in depressives. These data support he hypothesis of 
a decreased glucocorticoid receptor plasticity and a partial steroid resistance in depres- 
sion. 
Introduction 
Abnormalities of hypothalamic-pituitary-adrenal (HPA)system integrity linked to depres- 
sion include 24-hr hypersecretion f cortisol during depressive pisodes (Linkowski et al 
1985, 1987), inadequate suppressibility ofcortisol by dexamethasone (Carroll et al 1968), 
and hyperresponsiveness of the adrenal cortex to exogenous corticotropin [adrenoco~- 
topic hormone (ACTH)] (Amsterdam et al 1984). Moreover, hypersecretion of corti- 
cotropin-releasing hormone (CRH) has been detected in the cerebrospinal fluid of de- 
pressed patients (Nemeroff et al 1984). Studies on the application of ovine (Gold et al 
1984, 1986) and human (Holsboer et al 1984a, 1987; Rupprecht et al 1989a) CRH in 
depression have shown an attenuated response of ACTH in depressed patients, possibly 
related to hypercortisolemia (Gold et al 1986). However, recent investigations were unable 
to reproduce the blunted ACTH response to CRH in depression, when cortisol synthesis 
was previously blocked with the I 1-[3-hydroxylase inhibitor metyrapone (MET) (yon 
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Bardeleben et al 1988; Lisansky et al 1989). Instead, even an augmented ACTH response 
to CRH has been noted in depressives after equalizing the amount of the glucocorticoid- 
mediated feedback in all subjects (Lisansky et al 1989). 
An escape of plasma ACTH (Fang et al 1981) and I~-endorphin (Matthews et al 1986, 
Rupprecht et al 1988) from dexamethasone suppression i  endogenously depressed pa- 
tients provided evidence of a subtle derangement of the feedback regulation of the HPA 
system during depression. Moreover, reports of an inadequate suppression of prolactin 
(Meltzer et al 1982; Klein et al 1984; Rupprecht et al 1987) and thyroid-stimulating 
hormone (TSH) (Rupprecht et al 1989c) as well as an augmented reponse of the hypo- 
thalamic-pituitary-somatotropic (liPS) system (Rupprecht et al 1989b) following glu- 
cocort/coid administration i  depression have supported the idea that the derangement of 
the glucocorticoid-mediated n gative feedback is not only restricted to the HPA system 
but involves a variety of neuroendocrine systems. In addition, dexamethasone bioavail- 
ability has been shown to be lower in depressed patients wit~, -. positive dexamethasone 
suppression test (DST) (Holsboer et al 1984b; Lowy and Meltzer 1987; Holsboer et al 
1986), resulting in a shortened examethasone half-life m DST nonsuppressors due to 
an enhanced elimination of the test drug (Holsboer et al 1986). 
Several authors have investigated the potential role of glucocorticoid receptors (GR) 
in this context, with considerably different results. Some reports noted lower GR sites 
per cell in depressed patients (Gormley et al 1985; Whalley et al 1986), whereas others 
found a reduced ownregulation f GR concentrations only in DST nonsuppressors (Lowy 
et al 1988) or failed to detect differences between depressed patients and controls or 
between DST nonsuppressors and suppressors (Schlechte and Sherman 1985). 
Hypercortisolemia in depression represents a major confounding factor in accurate 
assessment of the HPA system and its feedback mechanism. The present study, designed 
to determine the effect of dexamethasone (DEX) administered in vivo on ACTH and [3- 
endorphin levels in relation to DEX plasma concentrations and GR autoregulation, avoided 
the potential effects of hypercortisolemia by metyrapone (MET)-induced blockage of 
cortisol synthesis. 
Subjects and Methods 
Subjects 
The patient group comprised 5 men and 13 women with unipolar major depressive disorder 
or bipolar depression aged between 18 and 72 years (mean _+ SD, 50.0 _+ 15.1 years), 
with a mean (+_ SD) body weight of 73.8 _+ 13.7 kg. The control group comprised 2
men and 12 women aged between 33 and 57 years (mean _+ SD, 47.1 __ 7.2 years), 
with a mean ( _+ SD) body weight of 68.4 +_ 10.1 kg. All subjects were carefully screened 
for prevalence ofmedical i lness that might influence pituitary-adrenal function by medical 
history, physical examination, and routine laboratory tests. Six female depressives and 
five female controls were tested uring the midluteal phase of the cycle; the other women 
were postmenopausal. DSM-III-R (American Psychiatric Association 1987) diagnoses 
were made on all patients by the consensus of two psychiatrists, who were blind to 
laboratory results. Severity of depression was assessed by the 21-item Hamilton Rating 
Scale for Depression (HRSD) (Hamilton 1960). The mean (_  SD) HRSD score of the 
patients was 27.2 _+ 4.6, ranging from 18 to 36. Patients were studied after a drug-free 
period of at least 72 hr. Details on clinical and demographic data of the patients and the 
medication given before the drug-free interval are shown in Table 1. 
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Table 1. Demographic Data, Antidepressants Prior to the Washout Period, and Diagnostic Description of 
the Depressed Patients 
Drag-free 
Patient Age period Treatment before Depressive 
no. (yr)/sex DSM-m-R HRS-D (d) drag-free period episodes 
1 441F Bipolar disorder, depressed 33 >28 
2 66/F MDD, recurrent, with melancholia 36 >28 
3 61/F MDD, recurrent, with melancholia, 28 >28 
mood congruent psychotic 
4 64/F MDD, recurrent, with melancholia 28 >28 
5 39/F MDD, recurrent 25 7 
6 60/M MDD, recurrent, with melancholia 24 5 
7 60/M MDD, recurrent, with melancholia 28 5 
8 34/F MDD, recurrent, with melancholia 28 4 
9 49/M MDD, single episode 21 7 
10 31/F Bipolar disorder, depressed 18 4 
11 55/F MDD, recurrent, with melancholia 26 5 
12 26/F MDD~ single episode with 26 4 
melancholia 
13 60/M Bipolar disorder, depressed 30 6 
14 57/F MDD, recurrent, with melancholia, 31 5 
mood congruent psychotic 
15 72/F MDD, recurrent 29 5 
16 54/F Bipolar disorder, depressed 33 >28 
17 18/F MDD, single episode 26 >28 
18 53/M MDD, recurrent 26 >21 
4 
Amitryptiline 100 nag 3 
Amitryptiline 100 nag 3 
Maprofiline 150 nag 3 
Maprotiline 100 nag 3 
Maprotiline 100 nag 1 
Lorazepam 3 nag 1 
Maprodline 150 mg 2 
Amitryptiline 75 nag 1 
Clomipramine 150 mg 6 
Mapmtiline 150 nag 2 
Amitryptiline 150 mg 
Controls had no history of psychiatric disorder and were medication free for at least 
4 weeks. 
Study Design 
After the nature of the study had been fully explained, written informed consent was 
obtained from patients and controls. The test protocol was approved by the ethics com- 
mittee of the University of Wth'zburg and the requirements of the revised version of the 
Helsinki Declaration were strictly fallowed. All subjects were admitted to a sleep labo- 
ratory unit at least 1 hr prior to drug administration r blood sampling. 
For determination f GR binding characteristics and hormone data 50 ml blood were 
collected at 4 PM into prechilled plastic tubes containing EDTA on three consecutive 
days. On day 1, baseline values were obtained. On day 2, the subjects were pretreated 
with 1.5 g MET at 9 AM administered orally with milk to avoid severe gastric symptoms. 
One milligram DEX was given orally at 11 PM. On day 3, administration f 1.5 g MET 
was given as described for day 2. The study design is summarized in Table 2. Eighty 
percent of the subjects experienced a transient dizziness and a hot flush after MET 
administration, which disappeared spontaneously within 45-60 min. 
Assays 
Glucocorticoid Receptor Assay. GR pharmacological characteristics were determined 
as described in detail elsewhere (Rupprecht et al 1990). A mononuclear cell fraction was 
prepared by sodium metrizoate-Ficoll density gradient centrifugation (Boyum 1968). Cells 
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Table 2. Description ofthe Study Design in Schematic Form 
Day 1 Day 2 
Blood sampling MET Blood sampling DEX 
(1.5 g) (1 rag) 
4 pM 9 AM 4 PM 11 PM 
Day 3 
Blood sampling 
(1.5 g) 
9 AM 4PM 
were washed two times in phosphate-buffered saline (PBS) for 10 min, incubated for 60 
min at 37°C to allow sufficient dissociation of endogenous hormone, and ~ben washed 
again. The final concentration f cells was determined using a Coulter Counter (Model 
$5, Coulter Electronics Ltd, England). Viability of cells exceeded 95%, as judged from 
their ability to exclude trypan blue. Contamination by erythrocytes was less than 10%, 
and contamination by granulocytes and monocytes was less than 8% and did not differ 
among the three test days or between patients and controls. 
Binding experiments were carried out at 37°C in plastic microtiter plates in a total 
volume of 0.25 ml using 106 cells per well. The displacing compound (final concentration 
10 ttmol/L unlabeled examethasone) was added immediately prior to the addition of 
[3H]dexamethasone (specific activity 84 Ci/mmol) to determine nonspecific binding. Sat- 
uration experiments were performed on each blood sample using increasing concentrations 
of [3H]dexamethasone from 1 to 40 nmol/L. Saturation experiments were performed at 
equilibrium after a 90-min incubation period. After incubation, bound ligand was separated 
from free ligand by rapid filtration through Scatron filters with a Titertek cell harvester 
(Scatron, England) by washing with PBS (pH - 7.4) at room temperature. The filters 
were transferred into plastic vials, 5 ml of a toluene-based scintillation cocktail was 
added, and they were monitored for tritium in a Beckman LS 1801 coanter at about 54% 
efficiency. All samples were assayed in triplicate with a variation within a single exper- 
iment of less than 7%. The interassay vaxiability was 7%. 
Hormone Assays. ACTH was measured by an IRNIA supplied by the Nichols Institute 
(San Juan Capistrano, CA), which does not require extraction procedures (Raft and 
Findling 1989). A soluble sandwich complex is formed by a nSl-labeled monoclonal 
antibody directed against N-terminal ACTH and a biotin-coupled polyclonal antibody 
against C-terminal ACTH. The sandwich complexes are bound by adding avidin-coated 
plastic bead. Unbound components are washed away and the radioactivity bound to the 
solid phase is monitored in a gamma counter. The lower detection limit was 1.5 pmol/L, 
and the intraassay and interassay coefficients of varie:tion were 3% and 6.8%, respectively. 
Valaes below the detection limit were recorded as 1.5 pmol/L. 
[3-EndorPhin was determin¢~ by radioimmunoassay (RIA) (ImmunoNuclear Corp, 
Stillwater, MN) after extraction with anti-13-endorphin a tibodies coupled to Sepharose 
(Rupprecht et al 1988, 1989a). The minimal detectable concentration was 1.5 pmol/L, 
arid the intraassay and interassay coefficients of variation were 6% and 8%, respectively. 
Cortisol was measured by a direct RIA (Stalla et al 1981). The lower detection limit 
was 25 nmol/L, and the intraassay and interassay coefficients of variation were 5% and 
9%, respectively. As there was a cross-reactivity of our cortisol antibody with 1 l-deoxy- 
cortisol of about 15%, determinations of cortisol values following MET adminis(ration 
would not be accurate and were excluded from further analysis. 
1 l-Deoxycortisol (1I-DOC) was determined by a radioimmunologic method escribed 
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Figure 1. Mean _ SE 1 l-deoxycortisol (11- 
DOC) concentrations i  depressed patients 
(solid bars, n = 18) and normal controls 
(shaded bars, n = 14). 
previously (Vecsei 1981). I1-DOC was extracted from plasma using ethylglycole and 
assayed irectly using an antibody raised against the C-3-oxime of the steroid. The lower 
detection limit was 1.5 nmol/L. The recovery was about 80%, and the intraassay and 
interassay coefficients of variation were 5% and 13%, respectively. Cross-reactivities 
were 1.5% with cortisol and 0.2% with DEX. DEX was measured inunprocessed plasma 
using a direct RIA method with antibodies raised against he C-3-oxime of DEX as 
described in detail elsewhere (Haack et al 1981). 
The lower detection limit was 0.5 nmol/L. The intraassay and interassay variations 
were 6.7% and 14.7%, respectively. 
Data Analysis 
Preliminary estimates of binding parameters from saturation experiments ,were provided 
by the EBDA program (McPershon 1983). Final estimates of binding parameters were 
determined with a computerized nonlinear, least-square gression analysis (Munson and 
Rodbard 1980). This weighted curve fitting program assumes binding according to the 
law of mass action to independent classes of bindi~lg sites. The results are expressed as 
the mean -4- SD, and as the mean _+ SE in Figures 1-5. 
Differences in receptor and hormone data within subjects were analyzed by analysis 
of variance (ANOVA) for repeated measurements. Differences between patients and 
controls and between depressive subgroups were analyzed by ANOVA followed by post 
hoc comparisons with Student's t-test. Additionally, the ANOVA was repeated with the 
cofactors age, HRSD score, and cortisol, ACTH, I I-DOC, and DEX concentrations. 
Contingency tables were analyzed by ×2 analysis with Yates correction. Correlation data 
were obtained by PeLson's product moment correlation. All significance l vels are two- 
tailed. 
Results 
Administration of MET resulted in a sufficient blockade of the 11-13-hydroxylase, as 
shown by the excessive rise in 11-DOC (Figure l) (p < 0.001), ACTH (Figure 2) (p < 
0.001), and 13-endorphin (Figure 3) (p < 0.001) in patients and controls, which was 
avoided by DEX pretreatment. Baseline cortisol values at 4 PM did not differ significantly 
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Figure 2. Mean _+ SE ACTH concentra- 
tions in depressed patients (solid bars, n 
- 18) and normal controls (shaded bars, 
n = 14). The asterisk indicates a signif- 
icant difference (p < 0.05). 
between patients (mean _+ SD, 253.1 _+ 115.7 nmol/L) and controls (mean - SD, 218.0 
_+ 74.5 nmol/L). Although 1 I-DOC concentrations did not differ between patients and 
controls under either test condition, depressed patients exhibited slightly higher ACTH 
concentrations after MET + DEX pretreatment (p < 0.05) (Figure 2). The corresponding 
[3-endorphin values just failed to reach statistical significance (p < 0.07). ACTH and 13- 
endorphin values were strongly correlated in the patient and control group as well as in 
both groups combined (r - 0.8, p < 0.001). Dexamethasone plasma levels were similar 
in depressives (mean _+ SD, 2.72 _+ 0.25 nmol/L) and controls (2.47 _+ 0.22 nmol/L). 
Of the 14 controls, 13 showed complete suppression of ACTH below the detection 
limit of the assay of ! 5 pmol/L following DEX administration ("ACTH suppressors"). 
In contrast, only 8 ot ~8 patients were able to suppress ACTH completely, whereas the 
remaining 10 patients had postdexamethasone ACTH levels ranging from 2.6 to 8.6 
pmol/L ("ACTH nonsuppressors"). X 2analysis with Yates correction indicated a signif- 
icantly greater proportion of "ACTH nonsuppressors" among the patients (p < 0.02). 
Surpri'si~gly, the_m was no difference in DEX plasma concentrations between ACTH 
nonsuppressors (mean +_ SD, 2.32 _+ 0.87 nmoFL)and suppressors (mean _ SD, 2.74 
- 0.90 nmol/L), while baseline cortisol values were significantly higher in ACTH non- 
B-Endorphin [pmol/L] 
15 
10 
BASELINE 
T 
MET MET + DEX 
Hgure 3. Mean _+ SE 13-endorphin con- 
centrations in depressed patients ( olid bars, 
n = 18) and normal controls (shaded bars, 
n = 14). 
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Figure 4. Mean +_ SE glucocorticoid re- 
ceptor sites per cell in depressed patients 
(solid bars, n = 15) and normal controls 
(shaded bars, n = 18). The asterisk in- 
dicates asignificant difference (p < 0.005). 
suppressors (mean _+ SD, 294.8 +-. 124.8 versus 206.5 _+ 72.4 nmol/L) (p < 0.05). 
There was no relationship among age, sex, HRSD score, depressive subtype, number of 
depres~,ive episodes, length of previous episode, length of the washout period, or treatment 
prior to the washout period and cortisol, ACTH, or I~-endorphin concentration. 
To determine the effects of baseline cortisol levels and ACTH, 11-DOC, and DEX 
plasma concentrations on GR binding characteristics in relation to diagnostic group as 
main effect, these factors were included as covariates in the ANOVA model for diagnostic 
group. With these covariates entered to allow for their maximum contribution, depressed 
patients had significantly fewer GR sites per cell (p < 0.005) (Figure 4) and a lower Kd 
(p < 0.04) (Figure 5) following MET administration when compared with controls. The 
covariates did not contribute significantly to the explanation of the variance. No significant 
difference could be observed with regard to baseline and MET + DEX pretreated test 
conditions. There was an inverse relationship between baseline cortisol and baseline GR 
sites per cell in the whole sample (r = - 0,63, p < 0.001) and in the patient group (r 
= - 0.72; p < 0.01) but not w;,thia the control group (r = 0.51, NS). GR binding 
parameters did not correlate with ACTH, 13-endorphin, 1 I-DOC, or DEX concentrations 
under either test condition. Moreover, the clinical features mentioned above showed no 
20 
15 
10 
KD [nM] 
BASELINE MET MET ÷ DEX 
Figure 5. Mean -+ SE Kd in depressed 
patients (solid bars, n = 18) and normal 
controls (shaded bars, n = 14). The as- 
terisk indicates asignificant difference (p 
< 0.04). 
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association with GR paradigms. There were no differences between patients drug free 
for more than 21 days, and those with a shorter washout period with regard to hormone 
or GR data. 
Discussion 
Although a variety of studies (Arana et al 1985) have replicated the frequently occurring 
attenuated response of cortisol to DEX in patients with major depressive disorder, the 
pathophysiology of DST nonsuppression remains till unsolved. It has been suggested 
that the positive DST reflects hypercortisolemia (Poland et al 1987), and studies on DEX 
pharmacokinetics have shown a decreased bioavailability in depressed DST nonsuppres- 
sors (Lowy and Meltzer 1987; Holsboer et al 1986) due to a shortened half-life of the 
test drug (Holsboer et al 1986). Thus, the metabolism of DEX may conVOlute to positive 
DST results. However, even if DEX plasma levels were covaried out, the degree of DST 
nonsuppression in depression would not be fully explained by DEX bioavailability (Poland 
et al 1987). 
The endocrine ffects of cortisol and DEX are mediated ¢ia the mineralocorticoid 
receptor (MR) (type I) in the hippocampus and preferentially via the GR (type Ii) in the 
hippocampus, the hypothalamus, and the pituitary (Arriza et al 1987; De Kloet and Reul 
1987). We therefore investigated whether the response of the HPA system to DEX as a 
reflection of GR function in vivo is still attenuated in depressed patients after eliminating 
by MET the competition of DEX with elevated endogenous cortisol in relation to DEX 
plasma concentrations. Although we did not find a significant elevation of 4 PM baseline 
cortisol, this does not exclude hypercortisolemia, since it was only a single point mea- 
surement and the HPA axis is relatively quiescent at this time (Amsterdam et al 1987). 
Further studies hould apply a multiple time point measurement to detect eventual shifts 
in the rhythm of ACTH or cortisol. There was an attenuated response of ACTH to DEX 
in depressives, with a significantly greater proportion of patients than controls with 
incomplete suppression of ACTH by DEX. These data show that the impaired response 
of ACTH and ~-endorphin endogenous depression previously described under baseline 
conditions (Fang et al 1981; Matthews et al 1986; Rupprecht et al 1988) still persists 
after depletion of endogenous cortisol. The attenuated response of ACTH to DEX in- 
dependent of hypercortisolemia and DEX bioavailability in depression lends support o 
the idea of a defect of GR function in vivo, as has been suggested by reports of an 
impaired response also of prolactin (Meltzer et al 1982; Rupprecht et al 1987) and TS!-! 
(Rupprecht et ~ 1989c) to DEX in depression. 
Our study of baseline GR binding characteristics did not reve~/any difference between 
depressed patients and controls or between ACTH nonsuppressors and suppressors. These 
findings confirm previous investigations (Schlechte and Sherman 198. ~ and suggest that 
the GR is not downregulated byhypercortisolemia in depression. However, other groups 
have reported lower GR sites in depression (Gormley et ai 1985; Whalley et al 1986). 
Although GR has been reported to be under autoregulatory control in animals (Reul et 
al 1987) and humans (Rupprecht et al 1990), the patients howed no changes of GR 
binding characteristics related to major shifts of glucocorticoid levels whereas the controls 
responded to depletion of endogenous cortisol with a marked rise in GR sites per cell. 
Thus, the inverse relation of GR sites avd co~isol levels in depressives but not in controls 
reflects steroid resistance rather than GR downregulation. This is fi~rther supported by 
the absence of clinical features of a Cushing's yndrome despite the remarkable hyper- 
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cortisolemia noted in some of the depressive patients (Gormley et al 1985). The decrease 
in GR affinity (increase in Kd) in controls probably reflects a competition of the MET- 
induced excess in 11-DOC with labeled DEX because high amounts of 1 I-DOC can also 
bind to GRs (De Kloet and Reul 1987) without affecting the estimation of GR sites per 
cell (Rupprecht et al 1990). The lack of this effect in depressives also points to steroid 
resistance. 
However, GR binding data did not correlate with the effect of DEX on ACTH secretion. 
It is important in this context hat the response of the HPA system to DEX is mediated 
via GR sites in the hippocampus, the hypothalamus, and the pituitary. The hippoeampal 
GR has been shown to underlie a more sensitive autoregulation than other brain regions 
(McEwen et al 1987). Although recent investigations showed a certain parallelism in the 
response to reserpine of the GR in the hippoeampus and in leukoeytes of rats (Lowy 
1990), the extrapolation from the measurement of peripheral GR regulation to central 
nervous GR regulation should only be made with caution. 
Hypercortisolemia in depression represents a major confounding factor in the assess- 
ment of the HPA system and in neurotransmitter studies by action via the GR, since 
immunocytoehemical procedures with monoclonal antibodies (Fuxe et al 1985) have 
shown GRs to be present in almost all brain regions, with relatively high concentrations 
in the hippocampus and the hypothalamus. After this effect is controlled for by depletion 
of endogenous cortisol with MET, our data suggest a decrease in GR plasticity with a 
partial steroid resistance invitro and in vivo in depressive patients. Monoclonal antibodies 
(Fuxe et al 1985) and cDNA (Okret et al 1986; Dong et al 1988) or cRNA (Kalinyak et 
al 1989) probes are promising tools for further elucidating the deficiency of the GR and 
the derangement of the HPA system in depression. 
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